Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AeroVironment IncAVAV · Entity 3683 | VP & Chief People Officer | July 02, 2021 | May 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AeroVironment Inc
Report date July 02, 2021 · Filed May 09, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,585 |
Reported balance
After 2021-07-02 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2021-07-02 · Grant · Acquired 888 · Balance 4,585 F1: This amendment is being filed to correct the number of RSAs granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted RSAs on July 2, 2021, to vest in 3 equal installments on each of July 11, 2022,2023 and 2024. F2: Due to the error described above, the Reporting Person's Form 4 filed on July 7, 2021, incorrectly reported that the number of shares held by the Reporting Person was 4,270 shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed to correct the number of RSAs granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted RSAs on July 2, 2021, to vest in 3 equal installments on each of July 11, 2022,2023 and 2024.
F2: Due to the error described above, the Reporting Person's Form 4 filed on July 7, 2021, incorrectly reported that the number of shares held by the Reporting Person was 4,270 shares of Common Stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SomaLogic, Inc.
Report date January 05, 2024 · Filed January 09, 2024
Section 16 reporting ended · disclosed 2024-01-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 1
1 source rowRow 1 · 2024-01-05 · Disposition to issuer · Disposed 17,143 · Balance 0 F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.71 · Expires 2032-06-06 | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-05 · Disposition to issuer · Disposed 210,157 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F3: The option vested as to 1/4th of the total grant on June 7, 2023, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2033-03-16 | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-05 · Disposition to issuer · Disposed 150,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F5: The option vests as to 1/4th of the total grant on March 17, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.04 · Expires 2033-08-15 | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-05 · Disposition to issuer · Disposed 27,250 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F6: The option vests as to 1/4th of the total grant on August 16, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-01-05 · Disposition to issuer · Disposed 19,005 · Balance 0 F7: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F9: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F8: The RSUs vest as to 1/3rd of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025, subject to the continued service of the Reporting Person on each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-01-05 · Disposition to issuer · Disposed 50,250 · Balance 0 F7: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F9: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F10: The RSUs vest as to 1/4th of the total grant on each of November 9, 2023, November 9, 2024, November 9, 2025 and November 9, 2026, subject to the continued service of the Reporting Person on each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-01-05 · Disposition to issuer · Disposed 25,000 · Balance 0 F7: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F9: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F11: The RSUs vest as to 1/4th of the total grant on each of March 17, 2024, March 17, 2025, March 17, 2026 and March 17, 2027, subject to the continued service of the Reporting Person on each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-01-05 · Disposition to issuer · Disposed 15,900 · Balance 0 F7: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F9: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F12: The RSUs vest as to 1/4th of the total grant on each of August 16, 2024, August 16, 2025, August 16, 2026 and August 16, 2027, subject to the continued service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger").
F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock.
F3: The option vested as to 1/4th of the total grant on June 7, 2023, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions.
F5: The option vests as to 1/4th of the total grant on March 17, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
F6: The option vests as to 1/4th of the total grant on August 16, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
F7: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration.
F8: The RSUs vest as to 1/3rd of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025, subject to the continued service of the Reporting Person on each vesting date.
F9: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time.
F10: The RSUs vest as to 1/4th of the total grant on each of November 9, 2023, November 9, 2024, November 9, 2025 and November 9, 2026, subject to the continued service of the Reporting Person on each vesting date.
F11: The RSUs vest as to 1/4th of the total grant on each of March 17, 2024, March 17, 2025, March 17, 2026 and March 17, 2027, subject to the continued service of the Reporting Person on each vesting date.
F12: The RSUs vest as to 1/4th of the total grant on each of August 16, 2024, August 16, 2025, August 16, 2026 and August 16, 2027, subject to the continued service of the Reporting Person on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2024 Filed Jan 9, 2024 21:52 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerRestricted Stock Unit · Derivative | 15,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001330 · doc4.xml · derivative · entry 8 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,900 shares Expires not disclosed F7 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F9 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F12 · derivative.exercise_date: The RSUs vest as to 1/4th of the total grant on each of August 16, 2024, August 16, 2025, August 16, 2026 and August 16, 2027, subject to the continued service of the Reporting Person on each vesting date. F12 · derivative.expiration_date: The RSUs vest as to 1/4th of the total grant on each of August 16, 2024, August 16, 2025, August 16, 2026 and August 16, 2027, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:52 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerRestricted Stock Unit · Derivative | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001330 · doc4.xml · derivative · entry 7 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F7 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F9 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F11 · derivative.exercise_date: The RSUs vest as to 1/4th of the total grant on each of March 17, 2024, March 17, 2025, March 17, 2026 and March 17, 2027, subject to the continued service of the Reporting Person on each vesting date. F11 · derivative.expiration_date: The RSUs vest as to 1/4th of the total grant on each of March 17, 2024, March 17, 2025, March 17, 2026 and March 17, 2027, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:52 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerRestricted Stock Unit · Derivative | 50,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001330 · doc4.xml · derivative · entry 6 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,250 shares Expires not disclosed F7 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F9 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F10 · derivative.exercise_date: The RSUs vest as to 1/4th of the total grant on each of November 9, 2023, November 9, 2024, November 9, 2025 and November 9, 2026, subject to the continued service of the Reporting Person on each vesting date. F10 · derivative.expiration_date: The RSUs vest as to 1/4th of the total grant on each of November 9, 2023, November 9, 2024, November 9, 2025 and November 9, 2026, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:52 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerRestricted Stock Unit · Derivative | 19,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001330 · doc4.xml · derivative · entry 5 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,005 shares Expires not disclosed F7 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F9 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F8 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025, subject to the continued service of the Reporting Person on each vesting date. F8 · derivative.expiration_date: The RSUs vest as to 1/3rd of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:52 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (Right to buy) · Derivative | 27,250 | Not disclosed Strike: $2.04 | Not disclosed |
DisclosureSEC source: 0001209191-24-001330 · doc4.xml · derivative · entry 4 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,250 shares Expires 2033-08-15 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F6 · derivative.exercise_date: The option vests as to 1/4th of the total grant on August 16, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:52 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (Right to buy) · Derivative | 150,000 | Not disclosed Strike: $2.30 | Not disclosed |
DisclosureSEC source: 0001209191-24-001330 · doc4.xml · derivative · entry 3 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2033-03-16 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F5 · derivative.exercise_date: The option vests as to 1/4th of the total grant on March 17, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:52 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (Right to buy) · Derivative | 210,157 | Not disclosed Strike: $5.71 | Not disclosed |
DisclosureSEC source: 0001209191-24-001330 · doc4.xml · derivative · entry 2 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 210,157 shares Expires 2032-06-06 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F3 · derivative.exercise_date: The option vested as to 1/4th of the total grant on June 7, 2023, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:52 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerCommon Stock | 17,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001330 · doc4.xml · nonDerivative · entry 1 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. Read SEC document |
| November 10, 2023 Filed Nov 14, 2023 17:24 UTC | SomaLogic, Inc. SLGC · Entity 95310 | SaleCommon Stock | 5,675 | $2.43 | $13,790.82 |
DisclosureSEC source: 0001209191-23-055204 · doc4.xml · nonDerivative · entry 2 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,143 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document |
| November 09, 2023 Filed Nov 14, 2023 17:24 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 16,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055204 · doc4.xml · derivative · entry 3 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,250 Underlying: Common Stock · 16,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total grant on each of November 9, 2023, November 9, 2024, November 9, 2025 and November 9, 2026, subject to the continued service of the Reporting Person on each vesting date. F3 · derivative.expiration_date: The RSUs vest as to 1/4th of the total grant on each of November 9, 2023, November 9, 2024, November 9, 2025 and November 9, 2026, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| November 09, 2023 Filed Nov 14, 2023 17:24 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Exercise / conversionCommon Stock | 16,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-055204 · doc4.xml · nonDerivative · entry 1 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| September 15, 2023 Filed Oct 2, 2023 18:31 UTC | SomaLogic, Inc. SLGC · Entity 95310 | SaleCommon Stock | 3,434 | $2.33 | $8,000.53 |
DisclosureSEC source: 0001209191-23-051193 · doc4.xml · nonDerivative · entry 2 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,068 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document |
| September 13, 2023 Filed Oct 2, 2023 18:31 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 9,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051193 · doc4.xml · derivative · entry 3 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,005 Underlying: Common Stock · 9,502 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025, subject to the continued service of the Reporting Person on each vesting date. F3 · derivative.expiration_date: The RSUs vest as to 1/3rd of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| September 13, 2023 Filed Oct 2, 2023 18:31 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Exercise / conversionCommon Stock | 9,502 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-051193 · doc4.xml · nonDerivative · entry 1 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 16:26 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantRestricted Stock Unit (RSU) · Derivative | 15,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046546 · doc4.xml · derivative · entry 2 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,900 Underlying: Common Stock · 15,900 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total grant on each of August 16, 2024, August 16, 2025, August 16, 2026 and August 16, 2027, subject to the continued service of the Reporting Person on each vesting date. F3 · derivative.expiration_date: The RSUs vest as to 1/4th of the total grant on each of August 16, 2024, August 16, 2025, August 16, 2026 and August 16, 2027, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 16:26 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 27,250 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001209191-23-046546 · doc4.xml · derivative · entry 1 Roelke Alison Marie · CIK 0001790262 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,250 Underlying: Common Stock · 27,250 shares Expires 2033-08-15 F1 · derivative.exercise_date: The option vests as to 1/4 of the total grant on August 16, 2024, and thereafter 1/36th of the total grant vest monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 18:38 UTC | AeroVironment Inc AVAV · Entity 3683 | SaleCommon Stock | 1,097 | $78.08 | $85,648.49 |
DisclosureSEC source: 0001567619-22-006873 · doc1.xml · nonDerivative · entry 1 Roelke Alison Marie · CIK 0001790262 · VP and Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,596 F1 · price: The price reported represents the weighted average price of shares sold. Shares were sold at varying prices in the range of $78.0752 - $79.0751. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 09, 2021 Filed Jul 13, 2021 23:27 UTC | AeroVironment Inc AVAV · Entity 3683 | Tax withholdingCommon Stock | 318 | $99.34 | $31,590.12 |
DisclosureSEC source: 0001567619-21-013329 · doc1.xml · nonDerivative · entry 1 Roelke Alison Marie · CIK 0001790262 · VP People & Culture 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,693 F1 · shares: Disposition made pursuant to a net settlement whereby shares of stock were tendered to satisfy tax withholding obligations arising in conjunction with the vesting of previously issued Restricted Stock Awards. Read SEC document |
| July 02, 2021 Filed Jul 8, 2021 01:16 UTC | AeroVironment Inc AVAV · Entity 3683 | Tax withholdingCommon Stock | 259 | $97.69 | $25,301.71 |
DisclosureSEC source: 0001567619-21-013099 · doc1.xml · nonDerivative · entry 2 Roelke Alison Marie · CIK 0001790262 · VP & Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,011 F2 · shares: Disposition made pursuant to a net settlement whereby shares of stock were tendered to satisfy tax withholding obligations arising in conjunction with the vesting of previously issued Performance Restricted Stock Units. Read SEC document |
| July 02, 2021 Filed Jul 8, 2021 01:16 UTC | AeroVironment Inc AVAV · Entity 3683 | GrantCommon Stock | 573 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013099 · doc1.xml · nonDerivative · entry 1 Roelke Alison Marie · CIK 0001790262 · VP & Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,270 F1 · shares: Awards vest in 3 equal installments on each of July 11, 2022, 2023 and 2024. Read SEC document |
| July 02, 2021 Filed May 9, 2022 23:44 UTC Amendment | AeroVironment Inc AVAV · Entity 3683 | GrantCommon Stock | 888 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-009854 · doc1.xml · nonDerivative · entry 1 Roelke Alison Marie · CIK 0001790262 · VP & Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,585 F1 · shares: This amendment is being filed to correct the number of RSAs granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted RSAs on July 2, 2021, to vest in 3 equal installments on each of July 11, 2022,2023 and 2024. F2 · balance_after: Due to the error described above, the Reporting Person's Form 4 filed on July 7, 2021, incorrectly reported that the number of shares held by the Reporting Person was 4,270 shares of Common Stock. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 22:45 UTC | AeroVironment Inc AVAV · Entity 3683 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 699 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012868 · doc1.xml · derivative · entry 2 Roelke Alison Marie · CIK 0001790262 · VP & Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 699 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Performance Restricted Stock Unit (PRSU) represents the contingent right to receive, following vesting, shares of the issuer's common stock. The resulting number of shares of the issuer's common stock acquired upon vesting of the PRSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, over a three-year performance period beginning on May 1, 2018 and ending on April 30, 2021. The target number of units subject to the award is presented in the table. The number of units that vest may be 0% to 200% of the target number of units, depending on performance. F1 · shares: Each Performance Restricted Stock Unit (PRSU) represents the contingent right to receive, following vesting, shares of the issuer's common stock. The resulting number of shares of the issuer's common stock acquired upon vesting of the PRSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, over a three-year performance period beginning on May 1, 2018 and ending on April 30, 2021. The target number of units subject to the award is presented in the table. The number of units that vest may be 0% to 200% of the target number of units, depending on performance. F1 · price: Each Performance Restricted Stock Unit (PRSU) represents the contingent right to receive, following vesting, shares of the issuer's common stock. The resulting number of shares of the issuer's common stock acquired upon vesting of the PRSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, over a three-year performance period beginning on May 1, 2018 and ending on April 30, 2021. The target number of units subject to the award is presented in the table. The number of units that vest may be 0% to 200% of the target number of units, depending on performance. F2 · derivative.exercise_date: Unless earlier forfeited under the terms of the PRSU, each PRSU vests and converts into shares of the issuer's common stock upon certification by the Company's Compensation Committee of the achievement of the performance metrics of the PRSUs (the "Certification Date"). F2 · derivative.expiration_date: Unless earlier forfeited under the terms of the PRSU, each PRSU vests and converts into shares of the issuer's common stock upon certification by the Company's Compensation Committee of the achievement of the performance metrics of the PRSUs (the "Certification Date"). F3 · derivative.underlying_shares: Upon conversion of the PRSUs, the Reporting Person received 748 shares of common stock. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 22:45 UTC | AeroVironment Inc AVAV · Entity 3683 | Exercise / conversionCommon Stock | 748 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012868 · doc1.xml · nonDerivative · entry 1 Roelke Alison Marie · CIK 0001790262 · VP & Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Performance Restricted Stock Unit (PRSU) represents the contingent right to receive, following vesting, shares of the issuer's common stock. The resulting number of shares of the issuer's common stock acquired upon vesting of the PRSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, over a three-year performance period beginning on May 1, 2018 and ending on April 30, 2021. The target number of units subject to the award is presented in the table. The number of units that vest may be 0% to 200% of the target number of units, depending on performance. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 22:54 UTC | AeroVironment Inc AVAV · Entity 3683 | SaleCommon Stock | 1,100 | $115.00 | $126,500.00 |
DisclosureSEC source: 0001567619-21-007159 · doc1.xml · nonDerivative · entry 1 Roelke Alison Marie · CIK 0001790262 · VP & Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,949 Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:08 UTC | AeroVironment Inc AVAV · Entity 3683 | Tax withholdingCommon Stock | 147 | $85.93 | $12,631.71 |
DisclosureSEC source: 0001567619-21-000672 · doc1.xml · nonDerivative · entry 1 Roelke Alison Marie · CIK 0001790262 · VP & Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,049 F1 · shares: Disposition made pursuant to a net settlement whereby shares of stock were tendered to satisfy tax withholding obligations arising in conjunction with the vesting of previously issued Restricted Stock. Read SEC document |
| July 10, 2020 Filed Jul 14, 2020 21:52 UTC | AeroVironment Inc AVAV · Entity 3683 | Tax withholdingCommon Stock | 310 | $76.42 | $23,690.20 |
DisclosureSEC source: 0001567619-20-013284 · doc1.xml · nonDerivative · entry 1 Roelke Alison Marie · CIK 0001790262 · VP People & Culture 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,196 F1 · shares: Disposition made pursuant to a net settlement whereby shares of stock were tendered to satisfy tax withholding obligations arising in conjunction with the vesting of previously issued Restricted Stock Awards. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 23:29 UTC | AeroVironment Inc AVAV · Entity 3683 | Tax withholdingCommon Stock | 257 | $77.02 | $19,794.14 |
DisclosureSEC source: 0001567619-20-012728 · doc1.xml · nonDerivative · entry 2 Roelke Alison Marie · CIK 0001790262 · VP People & Culture 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,506 F2 · shares: Disposition made pursuant to a net settlement whereby shares of stock were tendered to satisfy tax withholding obligations arising in conjunction with the vesting of previously issued Performance Restricted Stock Units. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 23:29 UTC | AeroVironment Inc AVAV · Entity 3683 | GrantCommon Stock | 727 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-012728 · doc1.xml · nonDerivative · entry 1 Roelke Alison Marie · CIK 0001790262 · VP People & Culture 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,763 F1 · shares: Awards vest in 3 equal installments on each of July 11, 2021, 2022 and 2023. F1 · price: Awards vest in 3 equal installments on each of July 11, 2021, 2022 and 2023. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 22:41 UTC | AeroVironment Inc AVAV · Entity 3683 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 654 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-012544 · doc1.xml · derivative · entry 2 Roelke Alison Marie · CIK 0001790262 · VP People & Culture 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 654 shares Expires 2020-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Performance Restricted Stock Unit (PRSU) represents the contingent right to receive, following vesting, shares of the issuer's common stock. The resulting number of shares of the issuer's common stock acquired upon vesting of the PRSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, over a three-year performance period beginning on May 1, 2017 and ending on April 30, 2020. The target number of units subject to the award is presented in the table. The number of units that vest may be 0% to 200% of the target number of units, depending on performance. F1 · shares: Each Performance Restricted Stock Unit (PRSU) represents the contingent right to receive, following vesting, shares of the issuer's common stock. The resulting number of shares of the issuer's common stock acquired upon vesting of the PRSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, over a three-year performance period beginning on May 1, 2017 and ending on April 30, 2020. The target number of units subject to the award is presented in the table. The number of units that vest may be 0% to 200% of the target number of units, depending on performance. F1 · price: Each Performance Restricted Stock Unit (PRSU) represents the contingent right to receive, following vesting, shares of the issuer's common stock. The resulting number of shares of the issuer's common stock acquired upon vesting of the PRSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, over a three-year performance period beginning on May 1, 2017 and ending on April 30, 2020. The target number of units subject to the award is presented in the table. The number of units that vest may be 0% to 200% of the target number of units, depending on performance. F2 · derivative.exercise_date: Unless earlier forfeited under the terms of the PRSU, each PRSU vests and converts into shares of the issuer's common stock upon certification by the Company's Compensation Committee of the achievement of the performance metrics of the PRSUs (the "Certification Date"). F2 · derivative.expiration_date: Unless earlier forfeited under the terms of the PRSU, each PRSU vests and converts into shares of the issuer's common stock upon certification by the Company's Compensation Committee of the achievement of the performance metrics of the PRSUs (the "Certification Date"). F3 · derivative.underlying_shares: Upon conversion of the PRSUs, the Reporting Person received 742 shares of common stock. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 22:41 UTC | AeroVironment Inc AVAV · Entity 3683 | Exercise / conversionCommon Stock | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-012544 · doc1.xml · nonDerivative · entry 1 Roelke Alison Marie · CIK 0001790262 · VP People & Culture 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Performance Restricted Stock Unit (PRSU) represents the contingent right to receive, following vesting, shares of the issuer's common stock. The resulting number of shares of the issuer's common stock acquired upon vesting of the PRSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, over a three-year performance period beginning on May 1, 2017 and ending on April 30, 2020. The target number of units subject to the award is presented in the table. The number of units that vest may be 0% to 200% of the target number of units, depending on performance. Read SEC document |
| January 04, 2020 Filed Jan 7, 2020 22:24 UTC | AeroVironment Inc AVAV · Entity 3683 | Tax withholdingCommon Stock | 148 | $67.31 | $9,961.88 |
DisclosureSEC source: 0001567619-20-000725 · doc1.xml · nonDerivative · entry 1 Roelke Alison Marie · CIK 0001790262 · VP People & Culture 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,294 F1 · shares: Disposition made pursuant to a net settlement whereby shares of stock were tendered to satisfy tax withholding obligations arising in conjunction with the vesting of previously issued Restricted Stock Awards. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.